No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PEN240621P280000
- 85.50
- 0.000.00%
15min DelayTrading Oct 16 09:38 ET
0.00High0.00Low
0.00Open85.50Pre Close0 Volume0 Open Interest280.00Strike Price0.00Turnover373.97%IV-12.92%PremiumJun 21, 2024Expiry Date107.76Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9757Delta0.0015Gamma1.60Leverage Ratio-0.3000Theta-0.0075Rho-1.56Eff Leverage0.0061Vega
Intraday
- 5D
- Daily
News
A Look At The Intrinsic Value Of Penumbra, Inc. (NYSE:PEN)
Revenues Tell The Story For Penumbra, Inc. (NYSE:PEN)
Penumbra, Inc.'s (NYSE:PEN) price-to-sales (or "P/S") ratio of 6.8x might make it look like a strong sell right now compared to the Medical Equipment industry in the United States, where around half o
Peering Into Penumbra's Recent Short Interest
Penumbra's (NYSE:PEN) short percent of float has fallen 9.16% since its last report. The company recently reported that it has 1.93 million shares sold short, which is 7.04% of all regular shares that
Why Is Penumbra (PEN) Down 4.8% Since Last Earnings Report?
Penumbra(PEN.US) Officer Sells US$113.34K in Common Stock
$Penumbra(PEN.US)$ Officer Roberts Johanna sold 600 shares of common stock on Jun 3, 2024 at an average price of $188.9 for a total value of $113.34K.Source: Announcement What is statement of changes
Penumbra, Inc. to Present at the Truist Securities MedTech Conference
Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Truist Securities MedTech Conference on Tuesday,...
Comments
Despite the high P/S ratio, shareholders are holding onto Penumbra's stocks due to its strong future revenue prospects. The strong revenue forecasts are expected to keep the share price buoyant unless the analysts have significantly misjudged the company's potential.
Penumbra, Inc.'s (NYSE:PEN) Earnings Haven't Escaped The Attention Of Investors
A new generation of highly effective weight-loss and diabetes drugs known as GLP-1s has led Wall Street to spell doom for companies that have profited from obesity problem. However, the reaction on Wall Street has been extreme, creating opportunities for cooler heads, some analysts and investors say.
To be sure, drugs such as $Novo-Nordisk A/S(NVO.US$'s Ozempic and Wegovy, and Eli Lilly's Mounjaro have p...
To be sure, drugs such as $Novo-Nordisk A/S(NVO.US$'s Ozempic and Wegovy, and Eli Lilly's Mounjaro have p...
10
Penumbra's earnings outlook could be brighter than reflected in the statutory profit due to one-off items. The company's profitability this year shows a good sign after previous losses.
Penumbra's low ROE and declining net income over five years hint at sub-par performance. The earnings' decline, despite profit retention, could imply a struggling business or high payout ratio. Analyst estimates, however, foresee a better earnings growth rate.
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after market closed (gaps range from large to small):
Gap Ups
1. $Vertiv Holdings(VRT.US$ - up 18.6%
2. $Erie Indemnity(ERIE.US$ - up 8.7%
3. $Aspen Technology(AZPN.US$ - up 6.5%
4. $Penske Automotive(PAG.US$ - up 5.1%
5. $Humana(HUM.US$ - up 3.7%
6. $Teva Pharmaceutical Industries(TEVA.US$ - up 3.7%
7. $Encompass Health(EHC.US$ - up 3.0%
8. $Emerson Electric(EMR.US$ - up 2.8...
Gap Ups
1. $Vertiv Holdings(VRT.US$ - up 18.6%
2. $Erie Indemnity(ERIE.US$ - up 8.7%
3. $Aspen Technology(AZPN.US$ - up 6.5%
4. $Penske Automotive(PAG.US$ - up 5.1%
5. $Humana(HUM.US$ - up 3.7%
6. $Teva Pharmaceutical Industries(TEVA.US$ - up 3.7%
7. $Encompass Health(EHC.US$ - up 3.0%
8. $Emerson Electric(EMR.US$ - up 2.8...
+16
11
Read more